News

Qualthera Health Corporation, dedicated to building a nationwide network of quality, patient-centered compounding pharmacies, has announced the official launch of Qualthera Pharmaceuticals Ltd. Co., a research-driven subsidiary

CSL Vifor and Travere Therapeutics, Inc., are pleased to announce that the European Commission has approved the conversion of the conditional marketing approval (CMA) into a standard marketing authorization (MA) for FILSPARI for the treatment

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical and technology company focused on developing innovative cell therapy platforms for cancer, autoimmune and infectious diseases, and Z Squared Inc., a Dogecoin mining company, today announced they have entered into

Boehringer Ingelheim and Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality approaches, have entered into a research collaboration and global license agreement.

Gene Solutions, a leading multinational biotech company specializing in advanced genetic testing, and Element Biosciences, a company democratizing access to advanced life science solutions, have entered into a strategic collaboration.

DAAN Biotherapeutics, a leading innovative drug development company specializing in T-Cell receptor (TCR)-based therapies, has signed an exclusive licensing agreement with GC Cell, a gene and cell therapy firm, for the tumor antigen-specific antibody sequence.

Rona Therapeutics, a biotechnology company pioneering innovative RNA-targeted therapies, announced that the Investigational New Drug (IND)

Avidity Biosciences, Inc. a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates

SparX Biopharmaceutical Corp. announced today that it will present clinical updates on its lead asset, SPX-303, a first-in-class anti-LILRB2/PD-L1 bispecific antibody